Shares of Genprex Inc. (GNPX) are surging over 53% in pre-market today, after the company announced a Patent and Technology License Agreement with The University of Texas MD Anderson Cancer Center for combination of its TUSC2 gene therapy with immunotherapies.
from RTT - Before the Bell https://ift.tt/2zfgsrj
via IFTTT
No comments:
Post a Comment